Compare KRMD & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | CNTN |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.4M | 153.8M |
| IPO Year | 2019 | 2021 |
| Metric | KRMD | CNTN |
|---|---|---|
| Price | $3.43 | $1.23 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.13 | N/A |
| AVG Volume (30 Days) | 173.2K | ★ 573.7K |
| Earning Date | 11-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.85 | ★ 88.10 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,127,366.00 | N/A |
| Revenue This Year | $17.24 | N/A |
| Revenue Next Year | $16.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.86 | $1.38 |
| 52 Week High | $6.61 | $5.27 |
| Indicator | KRMD | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 28.83 |
| Support Level | $3.00 | N/A |
| Resistance Level | $3.41 | $2.30 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 37.83 | 0.50 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.